F2RL1 and triple-A syndrome: Higher active basal TF expression was also observed in SMCs from AAA, which was inhibited by BAY 11-7082 (pharmacological inhibitor of IκK) and GB83 (pharmacological inhibitor of PAR-2).We demonstrated a PAR-2-mediated activation of the canonical NF-κB pathway, which triggers TF transcription in AAA.